<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126775</url>
  </required_header>
  <id_info>
    <org_study_id>INV-1006-Gna-1000-I</org_study_id>
    <nct_id>NCT01126775</nct_id>
  </id_info>
  <brief_title>Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 (Follow-up Studie)</brief_title>
  <official_title>Neuro-Prävention im Rahmen Des Interventionsprojektes INVADE-2 Systematische Prävention Bei Hochrisikopatienten für Schlaganfall Und vaskulär (Mit)Bedingte Demenz: Identifizierung Und Behandlung Von Stummen Hirninfarkten.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>INVADE gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>INVADE gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Silent&quot; strokes are more frequent than clinical apparent strokes and can be detected
      noninvasively by MRI-investigations of the brain. Persons with silent strokes have a
      considerably increased risk for clinical apparent strokes as well as for the development of
      dementia. Intention of the study is the detection of silent strokes and microbleedings by
      standardized cranial MRI in 1000 participants (500 high-risk and 500 low-risk persons for
      cerebrovascular accidents) after a standardized neurological and neuropsychological
      examination. Results will be the base of early detection and early preventive strategies of
      cerebrovascular accidents in high-risk persons.

      In the course of a systematic follow-up examination without MRI the same 1000 patients (500
      high-risk and 500 low-risk persons for cerebrovascular accidents) will be reinvited to the
      sites. In addition to the standardized neurological and neuropsychological examinations a
      surrogate parameter of nephropathy, microalbumin, will be examined as this parameter could be
      helpful in forecasting cerebral microangiopathy. The clinical investigation will be expanded
      by several tests in order to assess symptoms of cerebral microangiopathy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <primary_completion_date type="Anticipated">November 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>In the group of high-risk persons the percentage of silent strokes detected by MRI of the brain is significantly higher than in the group of non-high-risk persons.</measure>
    <time_frame>4/2012 until 11/2013</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of silent strokes by MRI in more than 10% of all subjects and diagnostic and therapeutic procedures refinancable near-term and in relation to long-term-consequences</measure>
    <time_frame>4/2012 until 11/2013</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of microbleedings by MRI in more than 10% of all subjects</measure>
    <time_frame>4/2010 until 11/2011</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>group non-high-risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>group high risk</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1000 participants of INVADE-2-study (&quot;Intervention project on cerebrovascular diseases and
        dementia in the district of Ebersberg, Bavaria&quot;)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed consent for NPV-2

          -  ongoing participation in INVADE-2

          -  completed participation in Neuroprävention study (NPV-1)

        Exclusion Criteria:

          -  not completed Neuroprävention study (Drop-out)

          -  disagreement of notification of incidental findings

          -  lack of capacity to consent of study participant

          -  lack of willingness to cooperate of study participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Hans Gnahn, Dr.</last_name>
    <email>hans@gnahn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid Biermeier</last_name>
    <email>biermeier@invade.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Praxis Dr. Briesenick u. Dr. Förstner</name>
      <address>
        <city>Baldham</city>
        <state>Bavaria</state>
        <zip>D-85598</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Briesenick, Dr.</last_name>
      <phone>+49 (0)8106</phone>
      <phone_ext>308866</phone_ext>
      <email>praxis@neuro-baldham.de</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Förstner, Dr.</last_name>
      <phone>+49 (0)8106</phone>
      <phone_ext>308866</phone_ext>
      <email>praxis@neuro-baldham.de</email>
    </contact_backup>
    <investigator>
      <last_name>Helmut Ambach, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Gnahn u. Dr. Klein</name>
      <address>
        <city>Ebersberg</city>
        <state>Bavaria</state>
        <zip>85560</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Gnahn, Dr.</last_name>
      <email>hans@gnahn.de</email>
    </contact>
    <contact_backup>
      <last_name>Julia Hartmann, Dr.</last_name>
      <email>hartmann@invade.de</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Gnahn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julia Hartmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Werner Klein, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Scherpinski U, Bickel H, Gnahn H, Förstl H, Conrad B, Sander D. [Intervention project on cerebrovascular diseases and dementia in the Ebersberg district (INVADE): rationale and design]. Nervenarzt. 2002 Dec;73(12):1199-204. German.</citation>
    <PMID>12486573</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2010</study_first_submitted>
  <study_first_submitted_qc>May 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2010</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Systematic prevention, stroke, vascular dementia, silent strokes, cerebral microangiopathy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

